Nanobody specific for oligomeric beta-amyloid stabilizes nontoxic form

Neurobiology of Aging

Volumn 33, Issue 7, 2012, Pages 1320-1328

  Kasturirangan, Srinath ^a   Li, Lin ^a   Emadi, Sharareh ^a   Boddapati, Shanta ^a   Schulz, Philip ^a   Sierks, Michael R ^a  

^a Arizona State University   (United States)

Author keywords

AFM; Alzheimer's disease; Beta amyloid; Nanobody; Oligomers

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; E1 NANOBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIBODY ISOLATION; ANTIGEN RECOGNITION; ARTICLE; ATOMIC FORCE MICROSCOPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN SYNTHESIS INHIBITION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; CELL LINE, TUMOR; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; PROTEIN BINDING;

EID: 84861185114     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.09.020     Document Type: Article

References (40)

1. Adams G.P., McCartney J.E., Tai M.S., Oppermann H., Huston J.S., Stafford W.F., Bookman M.A., Fand I., Houston L.L., Weiner L.M. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993, 53:4026-4034.
2. Barkhordarian H., Emadi S., Schulz P., Sierks M.R. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng. Des. Sel 2006, 19:497-502.
3. Birmingham K., Frantz S. Set back to Alzheimer vaccine studies. Nat. Med 2002, 8:199-200.
4. Colcher D., Bird R., Roselli M., Hardman K.D., Johnson S., Pope S., Dodd S.W., Pantoliano M.W., Milenic D.E., Schlom J. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl. Cancer Inst 1990, 82:1191-1197.
5. Emadi S., Barkhordarian H., Wang M.S., Schulz P., Sierks M.R. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J. Mol. Biol 2007, 368:1132-1144.
6. Emadi S., Kasturirangan S., Wang M.S., Schulz P., Sierks M.R. Detecting morphologically distinct oligomeric forms of alpha-synuclein. J. Biol. Chem 2009, 284:11048-11058.
7. Glabe C.G. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging 2006, 27:570-575.
8. Glenner G.G., Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun 1984, 122:1131-1135.
9. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol 2007, 8:101-112.
10. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
11. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
12. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554.
13. Huston J.S., McCartney J., Tai M.S., Mottola-Hartshorn C., Jin D., Warren F., Keck P., Oppermann H. Medical applications of single-chain antibodies. Int. Rev. Immunol 1993, 10:195-217.
14. Klein W.L., Krafft G.A., Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci 2001, 24:219-224.
15. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6448-6453.
16. Lambert M.P., Velasco P.T., Chang L., Viola K.L., Fernandez S., Lacor P.N., Khuon D., Gong Y., Bigio E.H., Shaw P., De Felice F.G., Krafft G.A., Klein W.L. Monoclonal antibodies that target pathological assemblies of Abeta. J. Neurochem 2007, 100:23-35.
17. Lambert M.P., Viola K.L., Chromy B.A., Chang L., Morgan T.E., Yu J., Venton D.L., Krafft G.A., Finch C.E., Klein W.L. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem 2001, 79:595-605.
18. Lee E.B., Leng L.Z., Zhang B., Kwong L., Trojanowski J.Q., Abel T., Lee V.M. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem 2006, 281:4292-4299.
19. Legrand C., Bour J.M., Jacob C., Capiaumont J., Martial A., Marc A., Wudtke M., Kretzmer G., Demangel C., Duval D. Lactate dehydrogenase (LDH) activity of the cultured eukaryotic cells as marker of the number of dead cells in the medium [corrected]. J. Biotechnol 1992, 25:231-243.
20. LeVine H. The challenge of inhibiting Abeta polymerization. Curr. Med. Chem 2002, 9:1121-1133.
21. LeVine H. Small molecule inhibitors of Abeta assembly. Amyloid 2007, 14:185-197.
22. Levites Y., Das P., Price R.W., Rochette M.J., Kostura L.A., McGowan E.M., Murphy M.P., Golde T.E. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest 2006, 116:193-201.
23. Liu R., Yuan B., Emadi S., Zameer A., Schulz P., McAllister C., Lyubchenko Y., Goud G., Sierks M.R. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 2004, 43:6959-6967.
24. Look G.C., Jerecic J., Cherbavaz D.B., Pray T.R., Breach J.C., Crosier W.J., Igoudin L., Hironaka C.M., Lowe R.M., McEntee M., Ruslim-Litrus L., Wu H.M., Zhang S., Catalano S.M., Goure W.F., Summa D., Krafft G.A. Discovery of ADDL - targeting small molecule drugs for Alzheimer's disease. Curr. Alzheimer Res 2007, 4:562-567.
25. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol 1991, 222:581-597.
26. Milenic D.E., Yokota T., Filpula D.R., Finkelman M.A., Dodd S.W., Wood J.F., Whitlow M., Snoy P., Schlom J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody. Cancer Res. CC49 1991, 51(23 Pt 1):6363-6371.
27. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
28. Ono K., Condron M.M., Teplow D.B. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14745-14750.
29. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
30. Rafii M.S., Aisen P.S. Recent developments in Alzheimer's disease therapeutics. BMC Med 2009, 7:7.
31. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci 2002, 3:824-828.
32. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
33. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med 2008, 14:837-842.
34. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
35. Walsh D.M., Klyubin I., Shankar G.M., Townsend M., Fadeeva J.V., Betts V., Podlisny M.B., Cleary J.P., Ashe K.H., Rowan M.J., Selkoe D.J. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans 2005, 33:1087-1090.
36. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., Trommer B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002, 924:133-140.
37. Wang M.S., Zameer A., Emadi S., Sierks M.R. Characterizing antibody specificity to different protein morphologies by AFM. Langmuir 2009, 25:912-918.
38. Wolfe M.S. Therapeutic strategies for Alzheimer's disease. Nat. Rev. Drug Discov 2002, 1:859-866.
39. Yokota T., Milenic D.E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992, 52:3402-3408.
40. Zameer A., Kasturirangan S., Emadi S., Nimmagadda S.V., Sierks M.R. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. J. Mol. Biol 2008, 384:917-928.